The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML).
Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML
26th June 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now